The invention provides separation media of substantially monodisperse populations of substantially spherical particles of polyarylketone polymers or of thio-analogues of such polymers, of selected sizes, and further provides containers, such as chromatographic columns and cartridges, containing substantially monodisperse populations of such particles.

The present invention relates to a process for the preparation of angiotensin receptor blockers or its pharmaceutically acceptable salts thereof containing less than 10 ppm of the azido impurities. More particularly, the present invention relates to process for the preparation of Losartan, Losartan potassium of Formula I or its other pharmaceutically acceptable salts thereof containing less than 10 ppm of each of the azido impurities, wherein the azido impurity is selected from the group comprising of 5-(4′-(azidomethyl)-[1,1′-biphenyl]-2-yl)-1H-tetrazole, 4′-(azidomethyl)-[1,1′-biphenyl]-2-carbonitrile, 4′-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-carbonitrile, 5-(4′-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-yl)-1H-tetrazole, 5-(azidomethyl)-2-butyl-4-chloro-1H-imidazole, 4′-((4-(azidomethyl)-2-butyl-5-chloro-1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-carbonitrile, 5-(4′-((4-(azidomethyl)-2-butyl-5-chloro-1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-yl)-1H-tetrazole and 1-((1-((2′-(1H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl)-5-(4′-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-yl)-1H-tetrazole. More particularly, the present invention relates to a simple, economical and industrially efficient process for the preparation of Losartan potassium of Formula I. The present invention also relates to solid oral pharmaceutical compositions and process for preparing solid oral pharmaceutical compositions comprising losartan or its pharmaceutically acceptable salts thereof and method of detecting azido impurities in these solid oral pharmaceutical compositions.

##STR00001##

Techniques for real-time or substantially real-time peak detection are described. In one embodiment, for example, logic coupled to memory may be configured to receive data from at least one analytical instrument and perform processing or analysis on the received data. Moreover, the logic may be configured to determine, via one or more GPUs or CPUs (or both), one or more peaks based on the processing or the analysis of the received data and generate peak detection data based on the detected one or more peaks in real-time or substantially real-time. Other embodiments are described.

Compositions and methods for analyzing disulfide bonds are provided. An exemplary method includes preparing peptide standards having no disulfide bonds, scrambled disulfide bond peptide standards, and native disulfide bond peptide standards according to the sequence of the region of the protein drug product that includes the disulfide bond, digesting a sample of protein drug product into peptides, separating the protein drug product peptides, analyzing the protein drug product peptides and the peptide standards, identifying scrambled and native disulfide bond peptides by retention time, and quantifying the level of scrambled disulfide bond peptides.

The present invention provides a method comprising a step of estimating the kidney function of an arbitrary subject by a regression analysis which employs the amount of a D, L-amino acid in a biological sample from the arbitrary subject as an explanatory variable and employs the amount of filtrated glomeruli in the arbitrary subject as an object variable, by employing a previously determined formula (I): Y=a.sub.1.Math.X.sub.1+a.sub.2.Math.X.sub.2+ . . . +a.sub.n.Math.X.sub.n+b (I) [wherein a.sub.1 to a.sub.n independently represent a constant obtained by the regression analysis; X.sub.1 to X.sub.n independently represent a variable of the amount of the D,L-amino acid which is selected by the regression analysis; and b represents a constant obtained by the regression analysis] on the basis of the Y value calculated from the amount of the D, L-amino acid in the biological sample from the object to be evaluated. Also provided is a system for carrying out the method.

A liquid chromatography system including a solvent delivery system, a sample delivery system in fluidic communication with solvent delivery system, a liquid chromatography column located downstream from the solvent delivery system and the sample delivery system, a detector located downstream from the liquid chromatography column, a thermal chamber housing at least one of the solvent delivery system, the sample delivery system, the liquid chromatography column and the detector, an engine configured to control the temperature in the thermal chamber, a heatsink operably connected to the engine, a first temperature sensor in the thermal chamber, a second temperature sensor, and a computer system configured to receive temperature information from each of the first and second temperature sensors, and implement a method for controlling temperature in the thermal chamber.

A pump unit includes a pump and a metal ion trap. The pump includes a metal member that comes into contact with a mobile phase. The pump pumps a mobile phase through a flow path. The metal ion trap includes a filter element. The filter element includes a metal ion retention structure for retaining metal ions by interacting with the metal ions included in a mobile phase. The filter element is provided in the flow path for a mobile phase pumped by the pump. The pump unit may be provided in a chromatograph.

A mobile phase monitor includes a measurement unit, an arithmetic unit, a storage, and a discrimination unit. The measurement unit measures a weight of a mobile phase container. The arithmetic unit produces a calibration curve indicating a relationship between a measurement value of the measurement unit and a liquid amount of the mobile phase accommodated in the mobile phase container. The arithmetic unit calculates the liquid amount of the mobile phase from the measurement value of the measurement unit based on the produced calibration curve. The storage stores a plurality of calibration curves respectively corresponding to a plurality of types of mobile phases. The discrimination unit discriminates a type of the mobile phase accommodated in the mobile phase container by searching for the produced calibration curve from the plurality of calibration curves stored in the storage.

There are provided a urine testing apparatus and a urine testing method which can stabilize urine vitamins for several days and improve testing accuracy and convenience of a urine collection test of a subject. According to this urine testing apparatus, the inner wall surface of a urine collection storage container is coated with an aqueous citric acid solution or the like as a urine stabilizer. Alternatively, a dried or freeze-dried aqueous citric acid solution or the like as the urine stabilizer is stored in the urine collection storage container. On the other hand, according to the urine testing method of this invention, the aqueous citric acid solution or the like as the urine stabilizer is added to the collected urine sample, the vitamin concentration of at least 7 days after urine collection is stabilized to stabilize each urine vitamin for several days, thereby improving the convenience of the urine collection test of the subject. In particular, the urine concentrations of vitamins B can be stabilized to accurately test the nutrients lacking in the body of the subject.

Anti-viral compounds with low cytotoxicity are identified from screening of products found in Red Sea sponges, including the sponge Stylissa carteri. The identified compounds can be brominated pyrrole-2-aminoimidazole alkaloids and derivatives thereof. Specific examples of identified compounds include oroidin, hymenialdisine, and debromohymenialdisine, as well as derivatives thereof. The compounds also can be useful scaffolds or pharmacores for further chemical modification and derivatization. Selected compounds, particularly oroidin, show selective anti-viral HIV-1 activity coupled with reduced cytotoxicity. The compounds can function as HIV reverse-transcriptase inhibitors, and molecular modeling can be used to confirm inhibition.